Skip to main content
. 2011;13(1):20–33.

Table 2.

Clinical Progression of BPH in the MTOPS Trial

Risk Reduction (95% CI)
Combination
Doxazosin and
Placebo Doxazosin Finasteride Finasteride
Endpoint (n = 737) (n = 756) (n = 768) (n = 786)
Clinical progression of BPH 39 (20–53) 34 (14–50) 66 (54–76)
≥ 4-point ↑ IPSS 45 (25–60) 30 (6–48) 64 (48–75)
AUR 35 (−31–67) 68 (21–87) 81 (44–93)
Invasive therapy due to BPH 3 (−48–37) 64 (34–80) 67 (40–82)

AUR, acute urinary retention; BPH, benign prostatic hyperplasia; CI, confidence interval; IPSS, International Prostate Symptom Score; MTOPS, Medical Therapy of Prostatic Symptoms. Data from McConnell JD et al.14